Acute Myeloid Leukemia (AML)

Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Significant progress in the characterization of molecular pathogenic events in acute myeloid leukemia (AML) has led to better characterization of prognosis and identification of subsets that are more likely to benefit from currently available strategies. Furthermore, deciphering…

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications

Original Publication Date
Article Source
External Web Content
Key Points The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML. MDS with a single TP53 mutation and CK is similar to MDS with biallelic TP53 abnormalities, whereas TP53-mutated AML is distinct…

ACROBAT interim results support AlloHeme for relapse prediction in AML, MDS

Original Publication Date
Article Source
External Web Content
Interim results of the ACROBAT study suggest that increasing microchimerism and loss of complete chimerism may indicate relapse risk in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The findings were presented in an oral abstract1 at the 2025…

Make Your Voice Count!

Join us in endorsing the recent appeal to Congress with the following actions. Your voice is important to continue these services for patients and provide opportunities for researchers to find the cures.

Read the letter to Congress from Research!America, with AAMDSIF and 600 other organizations, here.

Letter on the Bipartisan Senate FY25 Labor-HHS-Education Appropriations Bill

Original Publication Date
Article Source
Coalition Action
AAMDSIF is Taking a Stand for NIH Research Research programs led by the National Institutes of Health (NIH) forge the way for life-saving new treatments for rare diseases such as aplastic anemia, MDS, and PNH. With clinical research locations throughout the U.S., researchers and…

Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial

Original Publication Date
Article Source
External Web Content
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show “robust clinical activity” in patients newly diagnosed with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML)…
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.